News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Celgene International Sárl (CELG) Release: VIDAZA(R) AZA-001 Study Reports Unprecedented Survival Benefit in Higher-Risk MDS Extends to AML Patients



12/9/2008 10:26:42 AM

BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl (NASDAQ: CELG) today announced results from a subset analysis of the international phase III trial (AZA-001) demonstrating that the overall survival benefit observed in higher-risk MDS patients extends to patients with acute myeloid leukemia (AML). The data, presented at the 50th Annual Meeting of the American Society of Hematology (ASH), reported that patients with WHO-defined AML who were treated with VIDAZA (azacitidine) achieved significantly improved overall survival compared to those treated with a conventional care regimen (CCR).

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES